CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Sirolimus 1 MG/MLWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug472 Lopinavir / ritonavir tablets combined with Xiyanping injection Wiki 1.00
drug479 Lopinavir/ritonavir treatment Wiki 1.00
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials


1 A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)

This is a double-blinded, two-arm, randomized, placebo controlled study comparing the virological efficacy of add-on sirolimus with standard care to placebo and standard care. Virological efficacy is defined as the change from baseline to day 7 in SARS-CoV-2 viral burden measured by quantitative real-time polymerase chain reaction.

NCT04371640 SARS-CoV-2 Covid-19 Drug: Sirolimus 1 MG/ML Drug: Placebo

Primary Outcomes

Description: SARS-CoV-2 viral burden will be quantified for both arms using a qRT-PCR

Measure: Change in SARS-CoV-2 viral burden from baseline to day 7 of treatment

Time: Baseline, and days 1, 2, 3, 4, 5, 6, & 7 post-dose for all patients

Secondary Outcomes

Description: SARS-CoV-2 viral burden will be quantified for both arms using a qRT-PCR

Measure: Change in SARS-CoV-2 viral burden at days 1-6

Time: Days 1, 2, 3, 4, 5, and 6 post-dose for all patients

Description: Safety and tolerability of sirolimus in patients with COVID-19

Measure: Rate of treatment emergent adverse events

Time: Days 1, 2, 3, 4, 5, and 6 post-dose for all patients


No related HPO nodes (Using clinical trials)